SKU: B077  / 
    CAS Number: 216974-75-3

    Bevacizumab, Lyophilized powder

    RM3,548.25

    Bevacizumab is a recombinant humanized monoclonal antibody used in cancer research.  It can be used against vascular endothelial growth factor (VEGF).  It has also been used for ophthalmic research to investigate ocular disease processes.  

    Mechanism of Action Bevacizumab can inhibit tumor growth in a few different ways including inhibiting new blood vessel growth, altering vascular function and blood flow in tumor, and regression of newly formed tumor vasculature.  It inhibits antiogenesis via the inhibition of vascular endothelial growth factor A (VEGF-A).  VEGF-A is a growth factor protein that stimulates angiogenesis in a variety of diseases, especially cancer.  
    Cancer Research Applications In neurooncology, high-grade gliomas (HGGs) are malignant lethal tumors that have dismal prognosis despite advances in understanding molecular genetics, signaling pathways, cytoskeletal dynamics, and the role of stem cells in gliomagenesis.  These tumors are supprotred by vascular proliferation due to expression of vascular endothelial growth factor which is a molecular mediator.  Bevacizumab, due to its inhibition of VEGF-A, can be used in recurrent glioblastoma  (Rahmathulla G et al, 2013).
    Spectrum Bevacizumab is used in a variety of cancers including metastatic colon cancer, lung cancers, renal cancers, ovarian cancers, and breast cancer.
    Molecular Formula C6638H10160N1720O2108S44
    References

    Ellis LM (2006)  Mechanisms of action of Bevacizumab as a component of therapy for metastatic colorectal cancer. Seminars in Oncol. 33

    Gunther JB and Altaweel MM (2009)  Bevacizumab (Avastin) for the treatment of ocular disease. Survey Ophthalmol. 54(3):372-400

    Rahmathulla G, Hovey EJ, Hashemi-Sadraei N, Ahluwalia MS (2013)  Bevacizumab in high-grade gliomas: A review of its uses, toxicity assessment, and future treatment challenges. Onco Targets Ther. 6:371-389  PMID 23620671